Wolfgang Plischke - Evotec AG Insider

EVOTF -- USA Stock  

USD 19.65  2.17  12.41%

Chairman of the Supervisory Board
Prof. Dr. Wolfgang Plischke was Chairman of the Supervisory Board at Evotec AG since June 17, 2014. He is Chairman of the Remuneration and Nomination Committee at the Company. From March 2006 until April 2014 he was Member of the Board of Management of Bayer AG. He was responsible for Technology, Innovation and Sustainability and for the AsiaPacific region. From January 2002 to February 2006, he was Head of the Pharmaceuticals Business Group at Bayer AG with responsibility for the global business with prescription drugs. From 2000 to 2002, he served as Head of the Pharmaceuticals Business Group in North America at Bayer AG. From 1995 to 2000, Prof. Dr. Plischke served as President of Bayer Yakuhin Ltd., Japan, with responsibility for Pharmaceuticals and Consumer Care. He began his career in 1980 with Bayers subsidiary Miles Diagnostics after completing his biology studies at Hohenheim University. Prof. Dr. Plischke was Member of the Supervisory Board of Bayer AG since April 2016. He also holds a number of offices outside of Bayer AG. He is Member of the Board of the Walter Siegenthaler Society and the Robert Koch Foundation. He is also a Member of the senate of the Helmholtz association. In July 2011, Prof. Dr. Wolfgang Plischke was appointed honorary professor for Business Chemistry at the Ludwig Maximilian University of Munich.
Age: 65  Chairman Since 2014  Ph.D    
49 40 5 60 81 0  http://www.evotec.com
Wolfgang Plischke was Chairman of the Supervisory Board at Evotec AG since June 17, 2014. He is former member of the management board at Bayer AG.

Management Efficiency

The company has return on total asset (ROA) of 4.3 % which means that it generated profit of $4.3 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 6.24 % meaning that it generated $6.24 on every $100 dollars invested by stockholders.
The company has accumulated 212.96 M in total debt with debt to equity ratio (D/E) of 53.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Evotec AG has Current Ratio of 0.72 indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.

Similar Executives

Entity Summary

Evotec AG provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. Evotec AG was founded in 1993 and is headquartered in Hamburg, Germany. Evotec AG operates under Drug Manufacturers - Specialty Generic classification in USA and traded on OTC Market. It employs 2178 people.Evotec AG (EVOTF) is traded on OTC Market in USA. It is located in Manfred Eigen Campus and employs 2,178 people.

Evotec AG Leadership Team

Werner Lanthaler, CEO
Claus Braestrup, Executive
Michael Shalmi, Executive, MBA
Mario Polywka, COO, Ph.D
Mary Tanner, Executive
Roland Oetker, Chairman
Andreas Pinkwart, Executive
Paul Herrling, Executive, Ph.D
Colin Bond, CFO, MBA
Cord Dohrmann, Executive
Iris LoewFriedrich, Executive, Ph.D
Bernd Hirsch, Executive
Enno Spillner, CFO
Elaine Sullivan, Executive
Wolfgang Plischke, Chairman, Ph.D

Stock Performance Indicators

Current Sentiment - EVOTF

Evotec AG Investor Sentiment
Macroaxis portfolio users are insensible in their opinion about investing in Evotec AG. What is your opinion about investing in Evotec AG? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Evotec AG and U S Bancorp. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Additionally see Investing Opportunities. Please also try Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.